CC 91516
Alternative Names: CC-0776314; CC-91516Latest Information Update: 06 Jun 2022
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics
- Mechanism of Action Mitogen-activated protein kinase 1 inhibitors; Mitogen-activated protein kinase 3 inhibitors; Mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 02 Jun 2022 Preclinical trials in Cancer in USA (PO) prior to April 2022
- 08 Apr 2022 Pharmacodynamics data from a preclinical studies in Cancer presented at the 113th Annual Meeting of the American Association for Cancer Research(AACR-2022)
- 08 Apr 2022 Bristol Myers Squibb plans a clinical trial for Cancer